Please login to the form below

Not currently logged in
Email:
Password:

Zortress

This page shows the latest Zortress news and features for those working in and with pharma, biotech and healthcare.

Jobs to do

Jobs to do

having the potential for the management of Alzheimer's disease, or everolimus (Afinitor/ Zortress, originally developed for organ transplantation) in multiple types of cancer tumour.

Latest news

  • Novartis' Zortress cleared by FDA for liver transplants Novartis' Zortress cleared by FDA for liver transplants

    Novartis' Zortress cleared by FDA for liver transplants. Adds to kidney transplant indication in the US. ... Zortress/Certican achieved sales of $210m in transplantation, a rise of 20 per cent.

  • Antares hires Jonathan Jaffe as VP clinical development

    Antares hires Jonathan Jaffe as VP clinical development. His research experience includes time spent working on Novartis’ Zortress and Xolair. ... Drugs that Dr Jaffe has worked on during his time as a researcher include Novartis' Zortress (everolimus)

  • FDA approves Afinitor for pancreatic cancer

    In the US, everolimus is also available in different dosage strengths under the trade name Zortress for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving

  • FDA clears test for Novartis' Zortress

    FDA clears test for Novartis' Zortress. The US Food and Drug Administration has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress. ... The US Food and Drug Administration (FDA) has cleared a test that

  • Getting the GIST

    Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics